Nov 07, 2018 7:00am EST Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Oct 31, 2018 8:00am EDT Pieris Pharmaceuticals to Host Third Quarter 2018 Investor Call and Corporate Update on November 7, 2018
Oct 25, 2018 8:16am EDT Pieris Pharmaceuticals Appoints Matthew L. Sherman, M.D., to its Board of Directors
Oct 02, 2018 8:00am EDT Pieris Pharmaceuticals to Present Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/ONC0055 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep 14, 2018 8:00am EDT Pieris Pharmaceuticals to Present Preclinical Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the ERS International Congress 2018
Sep 10, 2018 8:00am EDT Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil. to its Board of Directors
Sep 04, 2018 8:00am EDT Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy
Aug 30, 2018 8:00am EDT Pieris Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
Aug 09, 2018 7:00am EDT Pieris Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
